Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | AHCY | P23526 | 10/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30138569 | 1.00 | ADORA2A (0.51) | ADORA2AAHCYADORA3SLC28A1SLC28A2 | |
| SCHEMBL25750428 | 0.92 | ADORA2A (0.51) | ADORA2AAHCYADORA3PI4KAPI4K2B | |
| SCHEMBL21078466 | 0.87 | AHCY (0.43) | ADORA2AAHCYADORA3 | |
| SCHEMBL21078589 | 0.86 | NT5E (0.48) | ADORA2AAHCYADORA3ADORA2BADORA1 | |
| SCHEMBL31228218 | 0.86 | NT5E (0.48) | ADORA2AAHCYADORA3ADORA2BADORA1 | |
| SCHEMBL16368187 | 0.86 | ADORA2A (0.49) | ADORA2AAHCYADORA3SLC28A1SLC28A2 | |
| SCHEMBL29722700 | 0.86 | ADORA2A (0.49) | ADORA2AAHCYADORA3SLC28A1SLC28A2 | |
| SCHEMBL29722780 | 0.86 | ADORA2A (0.56) | ADORA2AAHCYADORA3SLC28A1SLC28A2 | |
| SCHEMBL16368190 | 0.86 | ADORA2A (0.56) | ADORA2AAHCYADORA3SLC28A1SLC28A2 | |
| SCHEMBL19859805 | 0.84 | ADORA2A (0.62) | ADORA2AAHCYADORA3SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| WO-2021140471-A1 | METHOD FOR SYNTHESIS OF 2'-ALKYL- OR 2'-ALKENYL- OR 2'-ALKYNYL-4'-FLUORO-ADENOSINE DERIVATIVES AND INTERMEDIATES THEREOF | Janssen Biopharma, Inc. (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021140471-A1 | METHOD FOR SYNTHESIS OF 2'-ALKYL- OR 2'-ALKENYL- OR 2'-ALKYNYL-4'-FLUORO-ADENOSINE DERIVATIVES AND INTERMEDIATES THEREOF | Janssen Biopharma, Inc. (US) | 2021-07-15 | — | — | WO | disclosed |
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | HAVCR2, PNP, ENTPD5 | ADORA2A 270/4885AHCY 130/4885ADORA3 290/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ADORA2A 71/4885AHCY 444/4885ADORA3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.